Nexentis wins USPTO trademark registration for MitoCareX MITOLINE platform
PUBT · 05/05 11:34
Share
Listen to the news
- Nexentis Technologies received U.S. trademark registration from USPTO for MITOLINE, algorithm platform owned by its MitoCareX unit.
- Trademark grant strengthens protection for MitoCareX discovery engine used to model mitochondrial SLC25 carrier proteins for drug discovery.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Nexentis Technologies Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202605050732PRIMZONEFULLFEED9713211) on May 05, 2026, and is solely responsible for the information contained therein.
Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.
What's Trending